نتایج جستجو برای: her 2 proto oncogene protein

تعداد نتایج: 3535071  

Journal: :Cancer research 1994
R Mangues J M Kahn I Seidman A Pellicer

The induction of tumors with chemicals and the production of transgenic animals are two experimental approaches to study oncogene involvement in carcinogenesis. The combination of both strategies offers an excellent model system to study tumor development. This study analyzes the potential cooperation of N-methylnitrosourea (MNU) treatment and N-ras proto-oncogene overexpression in tumorigenesi...

Journal: :Molecular cancer therapeutics 2004
Minna Tanner Anita I Kapanen Teemu Junttila Olayinka Raheem Seija Grenman Jussi Elo Klaus Elenius Jorma Isola

Clinical resistance to the HER-2 oncogene-targeting drug trastuzumab (Herceptin) exists, but studies of the resistance mechanisms are hampered by the lack of suitable experimental model systems. We established a carcinoma cell line (designated JIMT-1) from a pleural metastasis of a 62-year old patient with breast cancer who was clinically resistant to trastuzumab. JIMT-1 cells grow as an adhere...

Journal: :Molecular and cellular biology 1991
A J Muller J C Young A M Pendergast M Pondel N R Landau D R Littman O N Witte

The c-abl proto-oncogene encodes a cytoplasmic tyrosine kinase which is homologous to the src gene product in its kinase domain and in the upstream kinase regulatory domains SH2 (src homology region 2) and SH3 (src homology region 3). The murine v-abl oncogene product has lost the SH3 domain as a consequence of N-terminal fusion of gag sequences. Deletion of the SH3 domain is sufficient to rend...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Nicola Tinari Rossano Lattanzio Clara Natoli Ettore Cianchetti Domenico Angelucci Enrico Ricevuto Corrado Ficorella Paolo Marchetti Saverio Alberti Mauro Piantelli Stefano Iacobelli

PURPOSE To assess the value of changes in the expression of topoisomerase IIalpha (TopoII) and the proto-oncogene erbB-2 (HER-2) as predictors of relapse-free survival in women with operable breast cancer treated with anthracycline-based neoadjuvant chemotherapy. PATIENTS AND METHODS Seventy-seven patients with primary breast cancer who had undergone neoadjuvant anthracycline-based chemothera...

2014
Isy Lima Peixoto Ana Maria Carreno Vania Mesquita Gadelha Prazeres Caroline Albuquerque Rodrigues Chirano Gabriel Maroja Ihara Patricia Bandeira de Melo Akel

Costello syndrome (CS) is a rare genetic disorder, first described by Costello in 1971, caused by mutations in the HRAS proto-oncogene. Clinical findings include facial dysmorphism, skin disorders, cognitive impairment, cardiac and musculoskeletal defects. There is an increased risk of malignancies in these patients, due to the proto-oncogene mutation, and also sudden death secondary to heart d...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید